+441518081136Comparison of efficacy and toxicity of carboplatin or cisplatin based chemo-radiotherapy treatment among elderly locally advanced non-small cell lung cancer patients
International Conference on Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
Mohamed Sheta, Omnia Abd –El-Fattah and Hanan A Alshenawy
Tanta University Hospital, Egypt
Scientific Tracks Abstracts : J Med Oncl Ther
Abstract:
Concurrent chemo-radiotherapy (CCRT) is the standard management for locally advanced non-small cell lung cancer (LA-NSCLC), but the definite choice of carboplatin or cisplatin-based chemo-radiotherapy as a treatment for elderly patients with LA-NSCLC has not yet been defined. In this study, we compared the efficacy and toxicity of Carboplatin vs. Cisplatin-based (CCRT) for elderly patients with LANSCLC. A study was conducted on 50 elderly patients (> 65 years) where 25 patients received. Carboplatin (area under the curve [AUC] 2) and Paclitaxel (45 mg/m2) administered on days 1, 8, 15, 22, 28, and 35 over a 6-week period; concurrent thoracic radiotherapy (RT) followed by two cycles of Paclitaxel 200 mg/m2 and Carboplatin AUC 6. The other 25 patients received 50 mg/m2 of Cisplatin administered on days 1, 8, 29, and 36, and 50 mg/m2/day of etoposide delivered on days 1–5 and 29–33; concurrent thoracic RT followed by Cisplatin 50 mg/m2 and etoposide 50 mg/m2 for two additional cycles. Both groups received thoracic RT dose ranged from 60 Gy to 70 Gy in 2 Gy per fraction, five fractions a week over six to seven weeks. Both Carboplatin and Cisplatin-based regimens had the similar overall survival but the Carboplatin is less toxic when combined with RT in elderly LA-NSCLC treated patients.
Biography:
Mohamed Sheta is a Lecturer of Clinical Oncology and Nuclear Medicine and Consultant of Clinical Oncology at Nile Hospital for Medical Insurance, Cairo in Tanta University. He has published his papers in reputed journals.
PDF HTML